PUBLIC COMPANY
save$SNYSanofi
$SNY39.58+0.18%Paris, FRupdated 9h ago
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in the Forbes Global 2000 was 89.
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval433 co-mentions · 217 sources
- company$SNYNFSanofi234 co-mentions · 225 sources
- drugRIFADIN233 co-mentions · 117 sources
- tagSmall Molecule168 co-mentions · 168 sources
- drugrifampin117 co-mentions · 117 sources
- drugRIFATER50 co-mentions · 25 sources
- drugPRIMAQUINE36 co-mentions · 18 sources
- drugrifapentine34 co-mentions · 17 sources
pipeline
27
marketed
1
phase 3
9
catalysts ytd
6
approvals ytd
1
recalls ytd
0
Pipeline(27)
view full pipeline →pipeline depth27 products
1Preclinical2Phase 112Phase 29Phase 31Marketed2pre_registration
Marketed
rilzabrutinib
Acquired (Autoimmune) Hemolytic Anemia
Tyrosine-protein kinase BTK
Phase 3Coronavirus Disease 2019 (COVID-19) vaccine
Coronavirus Disease 2019 (COVID-19)
Spike glycoprotein
Phase 3Fluzone QIV HD
Unspecified Influenza Virus Infections
Phase 3SP-0218
Yellow Fever
Phase 3VerorabVax
Rabies
Phase 3avalglucosidase alfa
Pompe Disease
Phase 3frexalimab
Relapsing Remitting Multiple Sclerosis (RRMS)
Phase 3gusacitinib hydrochloride
Hand Dermatitis
Phase 3riliprubart
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 3venglustat malate
Fabry Disease
Phase 2IIV-HD + rC19
Coronavirus Disease 2019 (COVID-19)
Phase 2RIV3 + rC19
Coronavirus Disease 2019 (COVID-19)
Upcoming
Recent(90d)
view all catalysts →Active trials
- phase2A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
- —Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
- —French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
- —Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
- phase4A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
- phase2A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission
- phase3A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- phase2A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
🐶 Hiring Signal
next earnings Oct 30, 2026
Where Sanofi is staffing up — a leading indicator of pipeline and commercial priorities.
News
- Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune diseaseBig Pharma-backed Nuvig Therapeutics has halted one of the two trials for its sole clinical asset after determining the program wouldn’t be able to advance quickly enough.fiercebiotech · 9h ago
- The top biopharma conferences in 2027Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.biopharma_dive · 11h ago
- Eli Lilly’s best-ever weight loss data; Sanofi, Regeneron re-up for $1B upfront; and moreWelcome back to another edition of Endpoints Weekly! It’s October 3rd, the day he asked me what day it was. “It’s October 3rd,” I told him. This week we had a number of prominent deals ...endpoints · 3d ago
- Sanofi, Regeneron broaden alliance to find their next DupixentThe deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.biopharma_dive · 5d ago
- Pfizer’s eczema drug clears skin in mid-stage trialDetailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.biopharma_dive · 5d ago
- Sanofi pays Regeneron $1B upfront to continue search for Dupixent successorSanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupi…biospace · 5d ago
- Sanofi builds on immunology alliance with Regeneron for $1B upfrontAs the patent cliff for Dupixent draws closer, Sanofi is turning back to the partnership that built the megablockbuster. The French pharma will pay $1 billion upfront to expand its antibody collabo…endpoints · 5d ago
- STAT+: Sanofi, Regeneron expand partnership after Dupixent successSanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.stat · 5d ago
- Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&DSanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage immunology programs, teeing the longstanding partners up to try to replicate Dupixent’s success.fiercebiotech · 5d ago
- The top 12 companies hiring in biopharma nowLooking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.biospace · 5d ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that